TLDR:
– BioAge Labs, a biotechnology company focused on developing therapies for obesity and metabolic diseases, has raised $170 million in Series D funding.
– The financing round was led by Sofinnova Investments, with participation from new investors including Longitude Capital, RA Capital, Cormorant Asset Management, and more.
– The funds will be used to advance Phase 2 clinical trials of azelaprag, an apelin receptor agonist, in combination with Lilly’s tirzepatide for the treatment of obesity in older adults.
